Urinary myelin basic protein-like material (MBPLM) represents material which is cross-reactive with a cryptic epitope in peptide 84-89 of human myelin basic protein. While normally present at moderate levels in the adult, these levels rise higher in patients who have secondary progressive multiple sclerosis (MS). The increase in urine MBPLM correlates with the burden of disease detected by T2-weighted cranial magnetic resonance imaging. There is no correlation between urinary MBPLM and acute disease activity in relapsing-remitting MS. The first major need for improving the clinical utility of measurements of MBPLM in urine in MS patients is to delineate its exact chemical features so that assays may be improved and a potential biological role of the MBPLM better understood. The second major task is to apply the group data accumulated and apply them to individual patients. This could prove to be means to individually direct treatment and determine its effectiveness.
Lublin FD , Reingold SC. (1996) Defining the clinical course of multiple sclerosis: Results of an international survey . Neurology46: 907-911 .
2.
The IFNB Multiple Sclerosis Study Group . (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology43: 655-661 .
3.
Paty DW , Li DKB , UBC MS/MRI Study Group , IFNB Multiple Sclerosis Study Group . (1993) Interferon beta- 1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology43: 662-667 .
4.
Jacobs LDet al. (1996) Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis . Ann Neurol39: 285-294 .
5.
Johnson KPet al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial . Neurology45: 1268-1276 .
6.
Noseworthy JH , O'Brien PC , Mayo Clinic-Canadian Cooperative MS Study Group . (1997) The Mayo Clinic-Canadian Cooperative study of sulfasalazine (Salazopyrin EN) in active multiple sclerosis: preliminary report . Neurology48: A340-A340 .
7.
Weiner HLet al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis . Science259: 1321-1324 .
8.
Andersen Oet al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis . Neurology47: 895-900 .
9.
Karussis DMet al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation . Neurology47: 341-346 .
10.
Whitaker JN , McFarland HF , Rudge P , Reingold SC. (1995) Outcomes assessment in multiple sclerosis clinical trials: A critical analysis . Multiple Sclerosis1: 37-47 .
11.
Bedell BJ , Narayana PA , Wolinsky JS. (1997) A dual approach for minimizing false lesion classifications on magnetic resonance images . MRM37: 94-102 .
12.
Rudick Ret al. (1997) Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol42: 379-382 .
13.
Whitaker JN , Snyder DS. (1982) Myelin components in the cerebrospinal fluid in diseases affecting central nervous system myelin . Clin Immunol Allergy2: 469-482 .
14.
Whitaker JN. (1998) Myelin basic protein in cerebrospinal fluid and other body fluids . Mult Scl4: 16-21 .
15.
Cuzner ML , Norton WT. (1996) Biochemistry of demyelination . Brain Pathol6: 231-242 .
16.
Morell P , Quarles RH , Norton WT. (1989) Formation, structure and biochemistry of myelin. In: Siegel G , Agranoff B , Albers RW , Molinoff P , (eds). Basic neurochemistryRaven Press: New York109-136.
17.
Roach Aet al. (1983) Characterization of cloned cDNA representing rat myelin basic protein: absence of expression in brain in shiverer mutant mice . Cell42: 799-806 .
18.
Campagnoni AT. (1988) Molecular biology of myelin proteins from the central nervous system . J Neurochem51: 1-14 .
19.
Kamholz J , deFerra F , Puckett C , Lazzarini RA. (1986) Identification of three forms of human myelin basic protein by cDNA cloning . Proc Natl Acad Sci USA83: 4962-4966 .
20.
Moscarello MA. (1990) Myelin basic protein: A dynamically changing structure. In: Hashim GA , Moscarello M , (eds.) Dynamic Interactions of Myelin ProteinsJohn Wiley: New York25-48.
21.
Hashim GA , Eylar EH. (1969) The structure of the terminal regions of the encephalitogenic basic protein from bovine myelin . Arch Biochem Biophys135: 324-333 .
22.
Ramwani JJ , Epand RM , Moscarello MA. (1989) Secondary structure of charge isomers of myelin basic protein before and after phosphorylation . Biochemistry28: 6538-6543 .
23.
Chou FC-H , Chou C-HJ , Shapira R , Kibler RF. (1976) Basis of microheterogeneity of myelin basic protein . J Biol Chem251: 2671-2679 .
24.
Deibler GE , Martenson RE. (1973) Chromatographic fractionation of myelin basic protein. Partial characterization and methylarginine contents of multiple forms . J Biol Chem248: 2392-2396 .
25.
Deibler GEet al. (1975) The contribution of phosphor-ylation and loss of COOH-terminal arginine to the microheterogeneity of myelin basic protein . J Biol Chem250: 7931-7938 .
26.
Baldwin GS , Carnegie PM. (1971) Isolation and partial characterization of methylated arginines from the encephalitogenic basic protein of myelin . Biochem J123: 69-74 .
27.
Wood DD , Moscarello MA. (1989) The isolation, characterization, and lipid-aggregating properties of a citrul-line containing myelin basic protein . J Biol Chem264: 5121-5127 .
28.
Fannon AM , Moscarello MA. (1990) Myelin basic protein is affected by reduced synthesis of myelin proteolipid proteininthe jimpy mouse . Biochem J268: 105-110 .
29.
Whitaker JNet al. (1992) An immunochemical comparison of human myelin basic protein and its modified, citrullinated form, C8 . J Neuroimmunol36: 135-146 .
30.
Martin Ret al. (1991) T-cell recognition of a citrulline-containing myelin basic protein . Neurology41: 257-258 .
31.
Whitaker JN , Chou CHJ , Chou FCH , Kibler RF. (1979) Antigenic regions for the humoral response to myelin basic protein . Mol Immunol16: 495-501 .
32.
Day ED , Potter NT. (1986) Monoclonal and polyclonal antibodies to myelin basic protein determinants . J Neuroimmunol10: 289-312 .
33.
Fallis RJ , Raine CS , McFarlin DE. (1989) Chronic relapsing experimental allergic encephalomyelitis in SJL mice following the adoptive transfer of an epitopespecific T cell line . J Neuroimmunol22: 93-105 .
34.
Sakai Ket al. (1988) Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein . J Neuroimmunol19: 21-32 .
35.
Offner Het al. (1989) T cell determinants of myelin basic protein include a unique encephalitogenic I-E-restricted epitope for Lewis rats . J Exp Med170: 355-367 .
36.
Warren KG , Catz I , Steinman L. (1995) Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B-cell epitope and a model of its features . Proc Natl Acad Sci USA92: 11061-11065 .
37.
Ota Ket al. (1990) T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis . Nature346: 183-187 .
38.
Bashir RM , Whitaker JN. (1980) Molecular features of immunoreactive myelin basic protein in cerebrospinal fluid of persons with multiple sclerosis . Ann Neurol7: 50-57 .
39.
Gibson BW , Gilliom RD , Whitaker JN , Biemann K. (1984) Amino acid sequence of human myelin basic protein peptide 45-89 as determined by mass spectrometry . JBiol Chem259: 5028-5031 .
40.
Whitaker JNet al. (1995) Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis . Ann Neurol38: 625-632 .
41.
Stoner GL. (1984) Predicted folding of b-structure in myelin basic protein . J Neurochem43: 433-447 .
42.
Zhou SR , Whitaker JN. (1990) An idiotype shared by monoclonal antibodies to different peptides of human myelin basic protein . J Immunol145: 2554-2560 .
43.
Zhou S-Ret al. (1998) A cross-reactive anti-myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis . Neurology50: 411-417 .
44.
Whitaker JN , Bashir RM , Chou C-H , Kibler RF. (1980) Antigenic features of myelin basic protein-like material in cerebrospinal fluid . J Immunol124: 1148-1153 .
45.
Percy AK , Goodwin J , Whitaker JN. (1996) Myelin basic protein-like material in urine: a developmental profile . Ann Neurol40: 297-297 .
46.
Whitaker JNet al. (1994) Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein-like material in patients with multiple sclerosis . Ann Neurol35: 577-585 .
47.
Whitaker JN , Chou CHJ , Chou FCH , Kibler RF. (1977) Molecular internalization of a region of myelin basic protein . J Exp Med146: 317-331 .
48.
Whitaker JN. (1984) Indicators of disease activity in multiple sclerosis: Studies of myelin basic protein-like materials . Ann NY Acad Sci436: 140-150 .
49.
Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) . Neurology33: 1444-1452 .
50.
Giovannoni G , Green A , Keir G , Thompson EJ. (1996) Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis - Letter to Editor . Ann Neurol40: 128-129 .
51.
Whitaker JN. (1987) The presence of immunoreactive myelin basic protein peptide in urine of persons with multiple sclerosis . Ann Neurol22: 648-655 .
